TipRanks
Guardant Health (GH)
NASDAQ:GH
US Market
GH
Guardant Health
RESEARCH TOOLSreports
Want to see GH full AI Analyst Report?

Guardant Health (GH) Stock Forecast & Price Target

2,283 Followers
See the Price Targets and Ratings of:

GH Analyst Ratings

Strong Buy
22Ratings
Strong Buy
22 Buy
0 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Guardant
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$197.42
▲(19.71% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $197.42 with a high forecast of $225.00 and a low forecast of $125.00. The average price target represents a 19.71% change from the last price of $164.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"61":"$61","226":"$226","102.25":"$102.3","143.5":"$143.5","184.75":"$184.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$225.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":197.42105263157893,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$197.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[61,102.25,143.5,184.75,226],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.41,169.07076923076923,173.73153846153846,178.3923076923077,183.05307692307693,187.71384615384616,192.3746153846154,197.0353846153846,201.69615384615383,206.35692307692307,211.0176923076923,215.67846153846153,220.33923076923077,{"y":225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.41,166.9493117408907,169.48862348178136,172.02793522267206,174.56724696356275,177.10655870445342,179.64587044534412,182.1851821862348,184.72449392712548,187.26380566801618,189.80311740890687,192.34242914979757,194.88174089068823,{"y":197.42105263157893,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.41,161.37846153846152,158.34692307692308,155.3153846153846,152.28384615384616,149.25230769230768,146.22076923076924,143.18923076923076,140.15769230769232,137.12615384615384,134.0946153846154,131.06307692307692,128.03153846153845,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.22,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.14,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.23,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.14,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.77,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.41,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$225.00Average Price Target$197.42Lowest Price Target$125.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$210→$225
Buy
36.43%
Upside
Reiterated
09/20/26
Guardant Health (GH) Gets a Buy from Goldman Sachs
Barclays Analyst forecast on GH
Luke Sergott
Barclays
Barclays
$200
Buy
21.27%
Upside
Reiterated
09/18/26
Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)
Craig-Hallum Analyst forecast on GH
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)
Piper Sandler Analyst forecast on GH
David Westenberg
Piper Sandler
Piper Sandler
$193
Buy
17.03%
Upside
Reiterated
09/15/26
Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)
UBS Analyst forecast on GH
Doug Schenkel
UBS
UBS
$175→$225
Buy
36.43%
Upside
Reiterated
09/09/26
Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS
Bernstein Analyst forecast on GH
Eve Burstein
Bernstein
Bernstein
$200→$210
Buy
27.33%
Upside
Reiterated
09/09/26
Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)
William Blair Analyst forecast on GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$203
Buy
23.09%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
BTIG Analyst forecast on GH
Mark Massaro
BTIG
BTIG
$195
Buy
18.24%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)
Mizuho Securities Analyst forecast on GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$200
Buy
21.27%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
J.P. Morgan Analyst forecast on GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$195
Buy
18.24%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)
Morgan Stanley Analyst forecast on GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$175→$185
Buy
12.18%
Upside
Assigned
08/04/26
Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley
Stephens Analyst forecast on GH
Mason Carrico
Stephens
Stephens
$195
Buy
18.24%
Upside
Reiterated
08/04/26
Stephens Remains a Buy on Guardant Health (GH)
Stifel Nicolaus Analyst forecast on GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$130→$180
Buy
9.14%
Upside
Reiterated
08/03/26
Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel
Canaccord Genuity Analyst forecast on GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$205
Buy
24.30%
Upside
Reiterated
08/02/26
Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on GH
Evie Koslosky
Goldman Sachs
Goldman Sachs
$210→$225
Buy
36.43%
Upside
Reiterated
09/20/26
Guardant Health (GH) Gets a Buy from Goldman Sachs
Barclays Analyst forecast on GH
Luke Sergott
Barclays
Barclays
$200
Buy
21.27%
Upside
Reiterated
09/18/26
Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Healthequity (HQY)
Craig-Hallum Analyst forecast on GH
William Bonello
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
09/15/26
Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)
Piper Sandler Analyst forecast on GH
David Westenberg
Piper Sandler
Piper Sandler
$193
Buy
17.03%
Upside
Reiterated
09/15/26
Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)
UBS Analyst forecast on GH
Doug Schenkel
UBS
UBS
$175→$225
Buy
36.43%
Upside
Reiterated
09/09/26
Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS
Bernstein Analyst forecast on GH
Eve Burstein
Bernstein
Bernstein
$200→$210
Buy
27.33%
Upside
Reiterated
09/09/26
Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)
William Blair Analyst forecast on GH
Matt Larew
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating
Rothschild & Co Redburn Analyst forecast on GH
Jamie Clark
Rothschild & Co Redburn
Rothschild & Co Redburn
$203
Buy
23.09%
Upside
Initiated
09/08/26
Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn
BTIG Analyst forecast on GH
Mark Massaro
BTIG
BTIG
$195
Buy
18.24%
Upside
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)
Mizuho Securities Analyst forecast on GH
Bradley Bowers
Mizuho Securities
Mizuho Securities
$200
Buy
21.27%
Upside
Reiterated
08/04/26
Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)
J.P. Morgan Analyst forecast on GH
Casey Woodring
J.P. Morgan
J.P. Morgan
$195
Buy
18.24%
Upside
Reiterated
08/04/26
J.P. Morgan Sticks to Its Buy Rating for Guardant Health (GH)
Morgan Stanley Analyst forecast on GH
Kallum Titchmarsh
Morgan Stanley
Morgan Stanley
$175→$185
Buy
12.18%
Upside
Assigned
08/04/26
Guardant Health price target raised to $185 from $175 at Morgan StanleyGuardant Health price target raised to $185 from $175 at Morgan Stanley
Stephens Analyst forecast on GH
Mason Carrico
Stephens
Stephens
$195
Buy
18.24%
Upside
Reiterated
08/04/26
Stephens Remains a Buy on Guardant Health (GH)
Stifel Nicolaus Analyst forecast on GH
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$130→$180
Buy
9.14%
Upside
Reiterated
08/03/26
Guardant Health price target raised to $180 from $130 at StifelGuardant Health price target raised to $180 from $130 at Stifel
Canaccord Genuity Analyst forecast on GH
Kyle Mikson CFA
Canaccord Genuity
Canaccord Genuity
$205
Buy
24.30%
Upside
Reiterated
08/02/26
Guardant Health: Buy Rating Reiterated as Strong Q2 Results, Raised 2026 Outlook Support Unchanged $205 Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARWRArrowhead Pharmaceuticals
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
ZVRAZevra Therapeutics
IMUXImmunic
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months
William BonelloCraig-Hallum
Success Rate
11/15 ratings generated profit
73%
Average Return
+37.57%
Copying William Bonello's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +37.57% per trade.
1 Year
William BonelloCraig-Hallum
Success Rate
15/15 ratings generated profit
100%
Average Return
+139.54%
Copying William Bonello's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +139.54% per trade.
2 Years
William BonelloCraig-Hallum
Success Rate
15/15 ratings generated profit
100%
Average Return
+307.29%
Copying William Bonello's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +307.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
7
7
1
0
0
Buy
32
40
64
50
52
Hold
2
2
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
49
66
50
52
In the current month, GH has received 52 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 197.42.
Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$0.75 with a range of -$0.92 to -$0.64. The previous quarter’s EPS was -$0.90. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s earnings estimate for GH is -$0.75 with a range of -$0.92 to -$0.64. The previous quarter’s EPS was -$0.90. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $350.79M with a range of $344.30M to $359.00M. The previous quarter’s sales results were $334.98M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.
Next quarter’s sales forecast for GH is $350.79M with a range of $344.30M to $359.00M. The previous quarter’s sales results were $334.98M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GH has Performed in-line its overall industry.

GH Stock Forecast FAQ

What is GH’s average 12-month price target, according to analysts?
Based on analyst ratings, Guardant Health’s 12-month average price target is 197.42.
    What is GH’s upside potential, based on the analysts’ average price target?
    Guardant Health has 19.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GH a Buy, Sell or Hold?
          Guardant Health has a consensus rating of Strong Buy which is based on 22 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Guardant Health’s price target?
            The average price target for Guardant Health is 197.42. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $225.00 ,the lowest forecast is $125.00. The average price target represents 19.71% Increase from the current price of $164.92.
              What do analysts say about Guardant Health?
              Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of GH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.